SARAH MONCEAUX: Open Payments
NPI 1356727796 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,050 in 127 payments from 15 companies in 2025. Trend: 2023 $641 · 2024 $852 · 2025 $2,050
Food & beverage: $2,050
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 30 | $421 |
| ABBVIE INC. | 20 | $285 |
| Alkermes, Inc. | 19 | $250 |
| Neurocrine BioSciences, Inc. | 7 | $161 |
| Axsome Therapeutics, Inc. | 11 | $159 |
| Teva Pharmaceuticals USA, Inc. | 10 | $139 |
| Janssen Pharmaceuticals, Inc | 7 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $117 |
| Vanda Pharmaceuticals Inc. | 5 | $113 |
| E.R. Squibb & Sons, L.L.C. | 3 | $70 |
Products named: VRAYLAR, REXULTI, ARISTADA, ABILIFY ASIMTUFII, INGREZZA, Auvelity, CAPLYTA, FANAPT.
Industry payments across LA — which companies pay providers there.
